Simplex3 20MG
$168.00
The world’s first quad-receptor research peptide — best value format. GIP + GLP-1 + Glucagon + Ghrelin — a retatrutide-class backbone with proprietary ghrelin prokinetic mechanism via PEG4 spacer. C18 diacid lipidation at Lys17 for once-weekly half-life targeting. 99% purity HPLC verified. LCMS mass confirmed. Batch-specific COA with every order. Patent pending. For laboratory research use only.
Simplex3 (20mg) — Quad-Receptor Research Overview
Simplex3 is a research-grade synthetic peptide representing the first quad-receptor agonist design in the GLP-class category. The 20mg vial is the best value format — double the research volume of the 10mg at a significantly lower cost per milligram. Suited for extended research protocols, multi-condition experimental designs, or comparative dose studies. LOT 006001 / BATCH 001.
Where retatrutide pioneered the triple GIP/GLP-1/Glucagon receptor stack, Simplex3 appends a fourth mechanism — partial ghrelin receptor (GHS-R1a) agonism — to the same backbone via a PEG4 molecular spacer.
The Four-Receptor Stack
GLP-1 receptor activity (31%) — glucose-dependent insulin secretion, satiety signaling, glucagon suppression.
GIP receptor activity (24%) — enhanced glucose-dependent insulin response, energy partitioning, reduced lipid storage at adipose tissue.
Glucagon receptor activity (22%) — increased resting energy expenditure, hepatic glucose modulation, enhanced fat oxidation.
Ghrelin receptor partial agonism (15%) — the novel fourth mechanism — GHS-R1a activation directly counteracts GLP-1-induced delayed gastric emptying. The root cause of nausea and vomiting in GLP-class research models is the gastric motility reduction that accompanies GLP-1 receptor activation. Ghrelin receptor partial agonism accelerates gastric emptying through the opposite pathway. Real-world data from SIMPLEX-G2 (same prokinetic mechanism at 7.5mg) documents appetite suppression with no GLP-class GI symptoms, validating the hypothesis prior to formal Simplex3 trials.
Structural Features
Proprietary ghrelin fragment (Gly-Ser-Dap(N-octanoyl)-Phe-NHâ‚‚) appended to a retatrutide-derived GIP/GLP-1/Glucagon backbone via PEG4 spacer. C18 diacid lipidation at Lys17 for albumin binding and once-weekly half-life targeting. Novel composition of matter. Patent pending.
Analytical Verification — LOT 006001 / BATCH 001
- Purity (HPLC): ≥ 99.0% — Pass
- Net weight: 20mg ± 0.3% — Pass
- Mass confirmation (LCMS): match within 0.5 Da — Pass
- Endotoxin: < 5 EU/kg — Pass
- Bioburden: < 10 CFU/vial — Pass
- Amino acid analysis: sequence verified — Pass
- Residual solvents: < ICH limits — Pass
- Water content (KF): < 3.0% w/w — Pass
What Every Vial Ships With
- Batch-specific Certificate of Analysis
- LCMS chromatogram and mass confirmation
- Endotoxin and residual solvent reports
- Reconstitution protocol and handling guide
- Cold-chain compatible packaging
Research Context
No controlled human clinical trial data exists for Simplex3. The ghrelin prokinetic mechanism is supported by peer-reviewed preclinical and clinical research on GHS-R1a agonists and by real-world observational data from SIMPLEX-G2. The GIP/GLP-1/Glucagon backbone is derived from published retatrutide structural data (LY3437943). Patent pending.
Not approved by the FDA for human or veterinary therapeutic use. Sold for laboratory research purposes only.
For laboratory research use only. Not intended for human or veterinary consumption. Not FDA approved for any indication.
Related products
